According to Zacks, “DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota. “
NASDAQ DMAC traded down $0.03 on Wednesday, reaching $2.82. 18,100 shares of the company were exchanged, compared to its average volume of 62,685. The business’s fifty day moving average price is $3.05 and its 200 day moving average price is $3.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.97 and a current ratio of 8.97. DiaMedica Therapeutics has a fifty-two week low of $1.70 and a fifty-two week high of $5.93.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. acquired a new position in DiaMedica Therapeutics during the second quarter worth $170,000. Granite Point Capital Management L.P. acquired a new position in shares of DiaMedica Therapeutics in the 2nd quarter valued at $1,141,000. BlackRock Inc. lifted its stake in shares of DiaMedica Therapeutics by 159.7% in the 2nd quarter. BlackRock Inc. now owns 27,075 shares of the company’s stock valued at $134,000 after purchasing an additional 16,651 shares during the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of DiaMedica Therapeutics in the 3rd quarter valued at $27,000. Finally, Worth Venture Partners LLC lifted its stake in shares of DiaMedica Therapeutics by 10.6% in the 2nd quarter. Worth Venture Partners LLC now owns 132,514 shares of the company’s stock valued at $657,000 after purchasing an additional 12,651 shares during the last quarter. 8.01% of the stock is currently owned by institutional investors.
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.
Featured Article: What is the Difference Between Common Shares and Convertible Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.